1204219-80-6 Usage
Description
Dapagliflozin-d5 is a labeled analogue of Dapagliflozin, a selective sodium-glucose cotransporter-2 (SGLT2) inhibitor. It is primarily used as an internal standard for the quantification of Dapagliflozin in various analytical techniques, such as gas chromatography (GC) or liquid chromatography (LC) mass spectrometry. Dapagliflozin-d5 plays a crucial role in ensuring accurate measurements and reliable results in the analysis of Dapagliflozin, which is a medication used to treat patients with type 2 diabetes.
Uses
Used in Pharmaceutical Industry:
Dapagliflozin-d5 is used as an internal standard for the quantification of Dapagliflozin in pharmaceutical research and development. It helps in the accurate measurement and analysis of Dapagliflozin levels, ensuring the quality and efficacy of the drug.
Used in Analytical Chemistry:
Dapagliflozin-d5 is used as an internal standard in GCor LC-mass spectrometry for the quantification of Dapagliflozin. It provides a reliable reference for the accurate determination of Dapagliflozin concentrations in various samples, such as biological fluids, pharmaceutical formulations, and environmental samples.
Used in Diabetes Treatment:
Dapagliflozin-d5 is used as a labeled analogue of Dapagliflozin, which is a selective SGLT2 inhibitor that reduces renal glucose reabsorption. This property makes Dapagliflozin an effective treatment for patients with type 2 diabetes, helping to lower blood glucose levels and manage the disease.
Check Digit Verification of cas no
The CAS Registry Mumber 1204219-80-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,4,2,1 and 9 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1204219-80:
(9*1)+(8*2)+(7*0)+(6*4)+(5*2)+(4*1)+(3*9)+(2*8)+(1*0)=106
106 % 10 = 6
So 1204219-80-6 is a valid CAS Registry Number.
1204219-80-6Relevant articles and documents
Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes
Xu, Ge,Lv, Binhua,Roberge, Jacques Y.,Xu, Baihua,Du, Jiyan,Dong, Jiajia,Chen, Yuanwei,Peng, Kun,Zhang, Lili,Tang, Xinxing,Feng, Yan,Xu, Min,Fu, Wei,Zhang, Wenbin,Zhu, Liangcheng,Deng, Zhongping,Sheng, Zelin,Welihinda, Ajith,Sun, Xun
, p. 1236 - 1251 (2014/03/21)
SGLT2 inhibitors deuterated at sites susceptible to oxidative metabolism were found to have a slightly longer tmax and half-life (t 1/2), dose-dependent increase in urinary glucose excretion (UGE) in rats, and slightly superior effects on UGE in dogs while retaining similar in vitro inhibitory activities against hSGLT2. In particular, deuterated compound 41 has the potential to be a robust long-acting antidiabetic agent.
ETHOXYPHENYLMETHYL INHIBITORS OF SGLT2
-
Page/Page column 36-37, (2010/05/13)
The present invention relates to new ethoxyphenylmethyl modulators of SGLT2, pharmaceutical compositions thereof, and methods of use thereof. (Formula I)